A Phase 1 interventional study of Bimekizumab regimen 1 iv and Bimekizumab regimen 2 iv in Psoriatic Arthritis and Axial Spondyloarthritis, sponsored by UCB Biopharma SRL. Recruiting at 65 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by UCB Biopharma SRL (part of UCB S.A.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Arthritis, Psoriatic by UCB S.A. — 2 open to participants now, 3 under way, 1 of them phase 3. Arthritis, Psoriatic · UCB S.A..
Among the 18 studies in Arthritis, Psoriatic by UCB S.A., this one is the 8th largest by planned enrollment of the 17 interventional ones that give a count, is one of 2 that started in 2025, is one of 6 in phase 1, and was the 18th registered.
601 studies on the registry are indexed under Arthritis, Psoriatic; 129 are open to participants now.
Browse Arthritis, Psoriatic studies →2 of the 18 studies in Arthritis, Psoriatic by UCB S.A. are open now, in 9 countries. Recruiting first, the newest first:
UCB Biopharma SRL · Sites in United States, Canada, Germany and 2 more countries
Ages 18+ · Women only
By country, each count listing its studies:
Of the 88 Arthritis, Psoriatic studies recruiting now, 53 (60%) set no upper age limit and 26 (30%) stop at 75 or younger; 12 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 392 is above the median of 145 across 337 interventional studies indexed under Arthritis, Psoriatic.
Median enrollment 214 across the 17 interventional studies, 1 across the 1 observational. Of the 15 that completed or were terminated, 11 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under UCB Biopharma SRL, one of the names counted as UCB S.A.. Under that name alone:
UCB Biopharma SRL is the lead sponsor of 130 studies on the registry; 18 are open to participants now.
Of its 71 completed or terminated interventional studies of FDA-regulated products, 50 (70%) have results posted.
1 of the studies in Arthritis, Psoriatic by UCB S.A. that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06506916Phase 3UCB Biopharma SRLA Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | 2027-03-09 |
Add it to your calendar (.ics) → With an account.
Among the 18 studies in Arthritis, Psoriatic by UCB S.A., from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To demonstrate that bimekizumab administered intravenously is noninferior to subcutaneous administration.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects participating in the study will receive assigned bimekizumab dosing regimen 1 or 2 during the PK Lead-In Phase and dosing regimen 1 or 2 during Treatment Period.
Drug: Bimekizumab regimen 1 iv · Drug: Bimekizumab regimen 2 iv
Subjects participating in the study will receive assigned bimekizumab dosing regimen 3 during the PK Lead-In Phase and dosing regimen 3 during Treatment Period.
Drug: Bimekizumab regimen 3 sc
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Participants will receive bimekizumab (BKZ) at pre-specified time points.
Steady-state Trough Concentration (Ctrough,ss) at Week 16
Steady-state trough concentration (Ctrough,ss) will be reported.
Time frame: Week 16
Occurrence of treatment-emergent Adverse Events (TEAEs) from Baseline to the end of Safety Follow-Up (SFU) Visit
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention.
Time frame: From Baseline to the end of SFU Visit (up to Week 29)
Occurrence of treatment-emergent Serious Adverse Events (SAEs) from Baseline to the end of SFU Visit
An SAE is any untoward medical occurrence that, at any dose, meets 1 or more of the criteria listed: Results in death; Is life-threatening; Requires inpatient hospitalization or prolongation of existing hospitalization; Results in persistent or significant disability/incapacity; Is a congenital anomaly/birth defect; Other situations: Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention.
Time frame: From Baseline to the end of SFU Visit (up to Week 29)
Occurrence of TEAEs leading to withdrawal of study intervention
An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. A TEAE is defined as any AE with a start on or after the first administration of study intervention and on or before 17 weeks after the final administration of study intervention. This includes AEs that worsen in intensity after the start of study intervention. TEAEs leading to withdrawal of IMP of the study will be reported.
Time frame: From Baseline to the end of SFU Visit (up to Week 29)
Plan to share: No — The sponsor does not plan to share IPD.
No publications or documents are linked to this record.
Started Dec 2025 (actual). Primary completion is estimated for May 2028, 29 months after the start.
Of 15 phase 1 interventional studies under Arthritis, Psoriatic, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 35. This study's planned 29 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.